Figure 2From: Control of the MYC-eIF4E axis plus mTOR inhibitor treatment in small cell lung cancerCharacteristics of SBC5 R1 and SBC5 R10 cells. (A) MTS assays with everolimus in SBC5, SBC5 R1 and SBC5 R10 cells. Data are expressed as the mean ± SD from 3 independent experiments. (B) Differentially expressed genes between SBC5 parent and SBC5 resistant cells by Gene-chip analysis (Fold change >10, <-10). (C) RTK phosphorylation associated with everolimus resistance in SBC5 cells. Ten differentially expressed RTKs between SBC5 parent and SBC5 R1 cells by RTK array (Fold change >1.5, <0.8). Only p-EGFR was overexpressed in both SBC5 R1 and SBC5 R10 cells (1.82-fold and 1.55-fold, respectively). (D) Protein expressions of three candidate molecules in SCLC cells by Western blot analysis. p-EGFR, EGFR, MYC and SPP1 were elevated in the two everolimus-resistant SBC5 cells. (E) FISH analysis for MYC. Red signal indicates 8q24. Green signal indicates D8Z2 probe (8cen). No evidence of MYC overexpression was found.Back to article page